MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders. The company's core technology is its proprietary Precision Endocrine Peptide (PEP) platform, which engineers peptides to overcome the limitations of native and modified peptide therapeutics. PEPs are designed to deliver optimized pharmaceutical properties, such as extended time-action profiles, consistent drug concentrations with low peak-to-trough ratios, and less frequent dosing, thereby improving clinical outcomes and simplifying disease management.
MBX's clinical pipeline targets diseases with significant unmet medical needs. Its lead product candidate, canvuparatide (MBX 2109), is a parathyroid hormone peptide prodrug in Phase 3 clinical trials for the treatment of chronic hypoparathyroidism. Canvuparatide is designed as a once-weekly subcutaneous injection to provide continuous, infusion-like exposure to parathyroid hormone. The company is also advancing imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist in Phase 2 development for post-bariatric hypoglycemia, and MBX 4291, a long-acting GLP-1/GIP receptor co-agonist in early-stage development for obesity. As a clinical-stage entity, MBX Biosciences does not currently generate product revenue and funds its operations through capital raises, including its 2024 initial public offering.
